EUCTR2008-000679-90-ES进行中（未招募）不适用
Estudio en Fase III, aleatorizado, doble ciego, multicéntrico, de grupos paralelos, controlado con placebo y con fármaco activo sobre la seguridad y eficacia de la optimización de dosis de Lisdexanfetamina Dimesilato (LDX) en niños y adolescentes de 6 a 17 años con Trastorno por Déficit de Atención con Hiperactividad (TDAH).A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)
Shire Pharmaceutical Development Limited0 个研究点目标入组 333 人开始时间: 2008年5月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 333
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The subject cannot be randomised before all inclusion criteria (including test results) are confirmed.
- •Subjects meeting all of the criteria listed below will be included in the study.
- •1. Subject’s parent or legally authorised representative (LAR) must provide signature of informed consent, and there must be documentation of assent (if applicable) by the subject indicating that the subject is aware of the investigational nature of the study and the required procedures and restrictions, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations before completing any study-related procedures.
- •2. Subject and parent/LAR are willing and able to comply with all the testing and requirements defined in this protocol, including oversight of morning dosing. Specifically, the parent/LAR must be available upon awakening, at approximately 7:00AM, to dispense the dose of study drug for the duration of the study.
- •3. Subject is a male or female aged 6-17 years inclusive at the time of consent.
- •4. Subject must meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition – Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation.
- •5. Subject must have a Baseline ADHD-RS-IV total score greater than or equal to 28.
- •6. Subject, who is a female of child-bearing potential (FOCP), must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test at Screening and a negative urine pregnancy test at Baseline and agree to comply with any applicable contraceptive requirements of the protocol
- •7. Subject has blood pressure measurements within the 95th percentile for age, gender, and height at Screening and Baseline.
- •8. Subject is functioning at an age-appropriate level intellectually, as deemed by the study investigator.
- •9. Subject is able to swallow a capsule.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects are excluded from the study if any of the following criteria are met at Screening or at Baseline (if reassessed).
- •1. Subject has failed to respond to more than one adequate course (dose and duration) of stimulant therapy. One course must have been a long-acting formulation.
- •2. Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any severe comorbid Axis II disorder or severe Axis I disorder (such as Post Traumatic Stress Disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, anorexia nervosa, severe depressive or severe anxiety disorder) or other symptomatic manifestations, such as agitated states, marked anxiety, or tension that, in the opinion of the examining clinician, will contraindicate treatment with LDX or CONCERTA XL or confound efficacy or safety assessments. Comorbid psychiatric diagnoses will be established with the Screening interview of the Kiddie-SADS-Present and Lifetime – Diagnostic Interview (K-SADS-PL) and additional modules if warranted by the results of the initial interview. Subjects may continue participating in behavioural therapy during this study as long as they have been receiving the therapy for at least 1 month at the time of the Baseline Visit.
- •3. Subject has a conduct disorder. Oppositional defiant disorder (ODD) is not exclusionary.
- •4. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments conducted in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional condition(s) that, in the Investigator’s opinion, would prohibit the subject from completing the study or would not be in the best interest of the subject. The additional condition(s) would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol. Mild, stable asthma is not exclusionary.
- •5. Subject is currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently, demonstrating active suicidal ideation.
- •6. Subject is female and is pregnant or lactating.
- •7. Subject has glaucoma.
- •8. Subject weighs less than 22.7kg (50lbs).
- •9. Subject is significantly overweight based on Centre for Disease Control and Prevention Body Mass Index (BMI)-for-age gender specific charts at Screening. Significantly overweight is defined as a BMI >97th percentile for this study.
- •10. Subject has a positive urine drug result at Screening (with the exception of subject’s current ADHD therapy).
- •11. Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating hormone (TSH) at Screening. Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
- •12. Subject has any clinically significant electrocardiogram (ECG) or laboratory abnormalities at Screening and/or Baseline.
- •13. Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or methylphenidate.
- •14. Subject has a documented allergy, hypersensitivity, or intolerance to any excipients in the test or reference products.
- •15. Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excludi
研究者
相似试验
进行中（未招募）
不适用
Estudio en Fase III, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia y seguridad de Progesterona en pacientes con Traumatismo Craneoencefálico SeveroEUCTR2010-018283-16-ESBHR Pharma, LLC1,180
进行中（未招募）
不适用
Estudio en fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico sobre la eficacia y la seguridad de cuatro ciclos de tratamiento de 12 semanas (48 semanas) con epratuzumab en pacientes con lupus eritematoso sistémico moderado a intenso (EMBODY2). - EMBODY 2upus Sistémico EritematosoMedDRA version: 12.1Level: LLTClassification code 10042945Term: Systemic lupus erythematosusEUCTR2010-018565-26-ESCB Inc.780
进行中（未招募）
不适用
Estudio en fase III, aleatorizado, doble ciego, controlado con un grupo paralelo con tratamiento activo para evaluar la eficacia y seguridad de BI 10773 en comparación con glimepirida administrados por vía oral durante 104 semanas en pacientes con diabetes mellitus de tipo 2 en tratamiento con metformina pero con un control glucémico insuficiente.A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks in patients with type 2 diabetes mellitus and insufficient glycaemic control despite metformin treatment.Diabetes mellitus de tipo 2 en tratamiento con metformina.Type 2 diabetes mellitus pre-treated with metforminMedDRA version: 12.1Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusEUCTR2009-016244-39-ESBoehringer Ingelheim España S.A1,400
进行中（未招募）
1 期
Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatitis A como control en la prevención de la infección cervical persistente por el HPV-16 o HPV-18 y del cáncer de cérvix, administrada por vía intramuscular conforme a la pauta de vacunación 0, 1 y 6 meses, en mujeres sanas entre 15 y 25 añosA phase III, double-blind, randomized, controlled study to evaluate the efficacy of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine compared to hepatitis A vaccines as control in prevention of persistent HPV-16 or HPV-18 cervical infection and cervical neoplasia, administered intramuscularly according to a 0, 1, 6 month schedule in healthy female subjects aged 15 – 25 years or age. - HPV-008cervical cancer => study is conducted in healthy femaleEUCTR2004-001325-14-ESGlaxoSmithKline SA18,644
进行中（未招募）
不适用
Estudio en Fase III, doble ciego, aleatorizado, de RAD001 10 mg/día más la mejor terapia de soporte frente a placebo más la mejor terapia de soporte, en el tratamiento de pacientes con tumor neuroendocrino pancreático (NET) avanzado - N/AEUCTR2006-006819-75-ESovartis Farmacéutica, S.A:392